Modulation of tumor immunity: a patent evaluation of WO2015026684A1

References

• Merck Sharp & Dohme Corp. Modulation of tumor immunity. WO2015026684. 2015.
   Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–1164.
   PubMed Web of Science ®Google Scholar
• Li X, Zheng Y. Regulatory T cell identity: formation and maintenance. Trends Immunol. 2015;36:344–353.
   PubMed Web of Science ®Google Scholar
• Sawant DV, Vignali DA. Once a Treg, always a Treg? Immunol Rev. 2014;259:173–191.
   PubMed Web of Science ®Google Scholar
• Morikawa H, Sakaguchi S. Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells. Immunol Rev. 2014;259:192–205.
   PubMed Web of Science ®Google Scholar
• Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 2006;66:4488–4495.
   PubMed Web of Science ®Google Scholar
• Geiger TL, Tauro S. Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function. Hum Immunol. 2012;73:232–239.
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Bacchetta R, et al. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol. 2014;380:39–68.
   PubMed Web of Science ®Google Scholar
• Bianchini R, Bistoni O, Alunno A, et al. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Eur J Immunol. 2011;41:2269–2278.
   PubMed Web of Science ®Google Scholar
• Nocentini G, Alunno A, Petrillo MG, et al. Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. Arthritis Res Ther. 2014;16:444.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759–767.
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167–1174.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–274.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538–18543.
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Remark R, et al. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol. 2014;27:8–15.
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010;33:435–441.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
   PubMed Web of Science ®Google Scholar
• Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999;59:3128–3133.
   PubMed Web of Science ®Google Scholar
• Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779–791.
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591–2601.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293–12297.
   PubMed Web of Science ®Google Scholar
• Borch TH, Donia M, Andersen MH, et al. Reorienting the immune system in the treatment of cancer by using anti- PD-1 and anti-PD-L1 antibodies. Drug Discov Today. 2015;20:1127–1134.
   PubMed Web of Science ®Google Scholar
• Calmels B, Paul S, Futin N, et al. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther. 2005;12:198–205.
   PubMed Web of Science ®Google Scholar
• Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005;202:885–891.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006;66:4904–4912.
   PubMed Web of Science ®Google Scholar
• Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol. 2006;176:6434–6442.
   PubMed Web of Science ®Google Scholar
• Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol. 2012;24:217–224.
   PubMed Web of Science ®Google Scholar
• Schaer DA. Hirschhorn-Cymerman D and Wolchok JD targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer. 2014;2:7.
   PubMedGoogle Scholar
• Clouthier DL, Watts TH. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev. 2014;25:91–106.
   PubMed Web of Science ®Google Scholar
• Croft M. The TNF family in T cell differentiation and function–unanswered questions and future directions. Semin Immunol. 2014;26:183–190.
   PubMed Web of Science ®Google Scholar
• Nocentini G, Giunchi L, Ronchetti S, et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA. 1997;94:6216–6221.
   PubMed Web of Science ®Google Scholar
• Kwon B, Yu KY, Ni J, et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem. 1999;274:6056–6061.
   PubMed Web of Science ®Google Scholar
• Gurney AL, Marsters SA, Huang RM, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 1999;9:215–218.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135–142.
   PubMed Web of Science ®Google Scholar
• McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311–323.
   PubMed Web of Science ®Google Scholar
• Gerli R, Nocentini G, Alunno A, et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev. 2009;8:426–430.
   PubMed Web of Science ®Google Scholar
• Petrillo MG, Ronchetti S, Ricci E, et al. GITR+ regulatory T cells in the treatment of autoimmune diseases. Autoimmun Rev. 2015;14:117–126.
   PubMed Web of Science ®Google Scholar
• Xiao X, Shi X, Fan Y, et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun. 2015;6:8266.
   PubMed Web of Science ®Google Scholar
• Kim IK, Kim BS, Koh CH, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med. 2015;21:1010–1017.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Schaer DA, Liu C, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010;5:e10436.
   PubMed Web of Science ®Google Scholar
• Ronchetti S, Ricci E, Petrillo MG, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res. 2015;2015:171520.
   PubMed Web of Science ®Google Scholar
• Sacchetti C, Rapini N, Magrini A, et al. In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes. Bioconjug Chem. 2013;24:852–858.
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685–1693.
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–4354.
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Sengupta S, Han Y, et al. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol. 2011;13:1308–1323.
   PubMed Web of Science ®Google Scholar
• Benevides L, Cardoso CR, Tiezzi DG, et al. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013;43:1518–1528.
   PubMed Web of Science ®Google Scholar
• Krausz LT, Fischer-Fodor E, Major ZZ, et al. GITR-expressing regulatory T-cell subsets are increased in tumor-positive lymph nodes from advanced breast cancer patients as compared to tumor-negative lymph nodes. Int J Immunopathol Pharmacol. 2012;25:59–66.
   PubMed Web of Science ®Google Scholar
• Padovani CT, Bonin CM, Tozetti IA, et al. Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection. Rev Soc Bras Med Trop. 2013;46:288–292.
   PubMed Web of Science ®Google Scholar
• Von Rahden BH, Kircher S, Kafka M, et al. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett’s mucosa. Cancer Biomark. 2010;7:285–294.
   PubMed Web of Science ®Google Scholar
• Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology. 2013;57:183–194.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11:3887–3895.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014;20:265–271.
   PubMed Web of Science ®Google Scholar
• Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32–38.
   PubMed Web of Science ®Google Scholar
• Chinai JM, Janakiram M, Chen F, et al. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36:587–595.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
   Google Scholar
• Burki TK. Pembrolizumab for patients with advanced melanoma. Lancet Oncol. 2015;16:e264.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.
   PubMed Web of Science ®Google Scholar
• Rizvi N, Brahmer J, Ou S-H, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(issue 15 supplement):8032.
   PubMed Web of Science ®Google Scholar
• Hamid O, Sosman J, Lawrence D, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31(issue 15 supplement):9010.
   PubMed Web of Science ®Google Scholar
• Spira A, Park K, Mazières J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol. 2015;33(issue 15 supplement):8010.
   Google Scholar
• Vical Incorporated. Synergistic antitumor efficacy using alloantigen combination immunotherapy. WO2013043569. 2013.
   Google Scholar
• Lu L, Xu X, Zhang B, et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med. 2014;12:36.
   PubMed Web of Science ®Google Scholar
• Nocentini G, Ronchetti S, Petrillo MG, et al. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol. 2012;165:2089–2099.
   PubMed Web of Science ®Google Scholar
• Nocentini G, Riccardi C. GITR: a modulator of immune response and inflammation. Adv Exp Med Biol. 2009;647:156–173.
   PubMed Web of Science ®Google Scholar
• Bossen C, Ingold K, Tardivel A, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem. 2006;281:13964–13971.
   PubMed Web of Science ®Google Scholar
• Krausz LT, Bianchini R, Ronchetti S, et al. GITR-GITRL system, a novel player in shock and inflammation. Sci World J. 2007;7:533–566.
   Web of Science ®Google Scholar
• Zhou Z, Song X, Berezov A, et al. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci USA. 2008;105:5465–5470.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Tone Y, Song X, et al. Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci USA. 2008;105:641–645.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay K, Ramagopal UA, Brenowitz M, et al. Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci USA. 2008;105:635–640.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, et al. Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: implications for function. Proc Natl Acad Sci USA. 2007;104:19452–19457.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT01239134. Trial of TRX518 (Anti-GITR mAb) in stage III or IV malignant melanoma or other solid tumors (TRX518-001). [ cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01239134?term=gitr&rank=2.
   Google Scholar
• ClinicalTrials.gov Identifier: NCT02132754. Study of MK-4166 and MK-4166 in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-4166-001). [ cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02132754.
   Google Scholar
• Schaer DA, Budhu S, Liu C, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Imunoll Res. 2013;1(5):320–331.
   Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125:2046–2058.
   PubMed Web of Science ®Google Scholar
• Coe D, Begom S, Addey C, et al. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother. 2010;59:1367–1377.
   PubMed Web of Science ®Google Scholar
• Carrier Y, Whitters MJ, Miyashiro JS, et al. Enhanced GITR/GITRL interactions augment IL-27 expression and induce IL-10-producing Tr-1 like cells. Eur J Immunol. 2012;42:1393–1404.
   PubMed Web of Science ®Google Scholar
• Van Olffen RW, Koning N, van Gisbergen KP, et al. GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol. 2009;182:7490–7500.
   PubMed Web of Science ®Google Scholar
• Ronchetti S, Zollo O, Bruscoli S, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol. 2004;34:613–622.
   PubMed Web of Science ®Google Scholar
• Kanamaru F, Youngnak P, Hashiguchi M, et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol. 2004;172:7306–7314.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay K, Lazar-Molnar E, Yan Q, et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol Rev. 2009;229:356–386.
   PubMed Web of Science ®Google Scholar
• Satoguina JS, Adjobimey T, Arndts K, et al. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta. Eur J Immunol. 2008;38:3101–3113.
   PubMed Web of Science ®Google Scholar
• Baltz KM, Krusch M, Bringmann A, et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 2007;21:2442–2454.
   PubMed Web of Science ®Google Scholar
• Tolerx Inc. GITR binding molecules and uses therefor. EP2343320. 2011.
   Google Scholar
• Merkck Sharp & Dohme Corp. Anti-GITR antibodies. US20140348841. 2014.
   Google Scholar
• Alunno A, Petrillo MG, Nocentini G, et al. Characterization of a new regulatory CD4+ T cell subset in primary Sjogren’s syndrome. Rheumatology (Oxford). 2013;52:1387–1396.
   PubMed Web of Science ®Google Scholar
• Tsaknaridis L, Spencer L, Culbertson N, et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res. 2003;74:296–308.
   PubMed Web of Science ®Google Scholar